Current Report Filing (8-k)
June 11 2021 - 11:18AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
June 9, 2021
Enzo Biochem, Inc.
(Exact Name of Registrant
as Specified in Its Charter)
New York
(State or Other Jurisdiction
of Incorporation)
001-09974
|
|
13-2866202
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
527 Madison Avenue
|
|
|
New York, New York
|
|
10022
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
(212) 583-0100
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b)
of the Act:
Title of Each Class
|
|
Trading Symbol
|
|
Name of Each Exchange on Which Registered
|
Common Stock, $.01 par value
|
|
ENZ
|
|
The New York Stock Exchange
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-1 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations
and Financial Condition
On June 9, 2021, Enzo Biochem, Inc. (the “Company”)
issued a press release announcing its operating results for its third fiscal quarter ended April 30, 2021. A copy of the press release
is furnished as Exhibit 99.1 attached hereto and is incorporated by reference in its entirety into this item 2.02 of this Current Report
on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
ENZO BIOCHEM, INC.
|
|
|
|
Date: June 11, 2021
|
By:
|
/s/ David Bench
|
|
|
David Bench
|
|
|
Chief Financial Officer
|
2
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Jul 2023 to Jul 2024